Catalent, A Covid Partner To Moderna, AstraZeneca, JNJ, Eyes Breakout.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): GALGANI, MATTHEW (AUTHOR)
  • Source:
    Investors Business Daily. 11/4/2021, pN.PAG-N.PAG. 1p.
  • Additional Information
    • Subject Terms:
      COVID-19; ASTRAZENECA PLC; COVID-19 pandemic; COVID-19 vaccines; MESSENGER RNA; MEDICAL research
    • Abstract:
      That lifted Catalent stock as much as 358% off its 2020 pandemic low until it pulled back in September. As Moderna (MRNA), Johnson & Johnson (JNJ), AstraZeneca (AZN) and other drugmakers have pushed to develop and mass produce Covid-19 vaccines and related therapies, they've turned to Catalent (CTLT) for support. [Extracted from the article]
    • Abstract:
      Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)